Inmune Bio CMO Resigns, Interim Appointed
Ticker: INMB · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Inmune Bio's CMO is out, interim CMO in. No drama, just a shuffle.
AI Summary
On April 8, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of Dr. David M. Daniels from his role as Chief Medical Officer. The company also announced the appointment of Dr. Gregory T. Poore as interim Chief Medical Officer, effective immediately. Dr. Daniels' departure is not related to any disagreements with the company's policies or practices.
Why It Matters
This leadership change in a key medical role could impact the company's ongoing research and development strategies and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in a biotech company, can introduce uncertainty regarding strategic direction and operational continuity.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Dr. David M. Daniels (person) — Resigning Chief Medical Officer
- Dr. Gregory T. Poore (person) — Appointed Interim Chief Medical Officer
- April 8, 2024 (date) — Effective date of report and Dr. Poore's appointment
FAQ
Who has been appointed as the interim Chief Medical Officer for Inmune Bio, Inc.?
Dr. Gregory T. Poore has been appointed as the interim Chief Medical Officer.
When did the change in Chief Medical Officer become effective?
The change became effective on April 8, 2024.
What is the reason cited for Dr. David M. Daniels' resignation?
Dr. David M. Daniels' resignation is not related to any disagreement with the company's accounting and financial disclosure policies or practices.
What is Inmune Bio, Inc.'s principal executive office address?
The principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the SIC code for Inmune Bio, Inc.?
The Standard Industrial Classification (SIC) code for Inmune Bio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-04-09 16:58:41
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0203559-8k_inmune.htm (8-K) — 26KB
- ea020355901ex99-1_inmune.htm (EX-99.1) — 26KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-031637.txt ( ) — 237KB
- inmb-20240408.xsd (EX-101.SCH) — 3KB
- inmb-20240408_lab.xml (EX-101.LAB) — 33KB
- inmb-20240408_pre.xml (EX-101.PRE) — 22KB
- ea0203559-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On April 8, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that the Company was presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC) . A copy of the press release is attached herewith as Exhibit 99.1.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated April 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: April 9, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2